Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma : the Fondazione Italiana Linfomi MCL0208 trial
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
In the Fondazione Italiana Linfomi MCL0208 phase 3 trial, lenalidomide maintenance (LEN) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL) improved progression-free survival (PFS) vs observation (OBS). The host pharmacogenetic background was analyzed to decipher whether single-nucleotide polymorphisms (SNPs) of genes encoding transmembrane transporters, metabolic enzymes, or cell-surface receptors might predict drug efficacy. Genotypes were obtained via real-time polymerase chain reaction of the peripheral blood germ line DNA. Polymorphisms of ABCB1 and VEGF were found in 69% and 79% of 278 patients, respectively, and predicted favorable PFS vs homozygous wild-type (WT) in the LEN arm was 3-year PFS of 85% vs 70% (P < .05) and 85% vs 60% (P < .01), respectively. Patients carrying both ABCB1 and VEGF WT had the poorest 3-year PFS (46%) and overall survival (76%); in fact, in these patients, LEN did not improve PFS vs OBS (3-year PFS, 44% vs 60%; P = .62). Moreover, the CRBN polymorphism (n = 28) was associated with lenalidomide dose reduction or discontinuation. Finally, ABCB1, NCF4, and GSTP1 polymorphisms predicted lower hematological toxicity during induction, whereas ABCB1 and CRBN polymorphisms predicted lower risk of grade ≥3 infections. This study demonstrates that specific SNPs represent candidate predictive biomarkers of immunochemotherapy toxicity and LEN efficacy after ASCT in MCL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Blood advances - 7(2023), 14 vom: 25. Juli, Seite 3764-3774 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferrero, Simone [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 31.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2022009504 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355626349 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355626349 | ||
| 003 | DE-627 | ||
| 005 | 20231226064736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2022009504 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355626349 | ||
| 035 | |a (NLM)37058477 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferrero, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma |b the Fondazione Italiana Linfomi MCL0208 trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 31.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a In the Fondazione Italiana Linfomi MCL0208 phase 3 trial, lenalidomide maintenance (LEN) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL) improved progression-free survival (PFS) vs observation (OBS). The host pharmacogenetic background was analyzed to decipher whether single-nucleotide polymorphisms (SNPs) of genes encoding transmembrane transporters, metabolic enzymes, or cell-surface receptors might predict drug efficacy. Genotypes were obtained via real-time polymerase chain reaction of the peripheral blood germ line DNA. Polymorphisms of ABCB1 and VEGF were found in 69% and 79% of 278 patients, respectively, and predicted favorable PFS vs homozygous wild-type (WT) in the LEN arm was 3-year PFS of 85% vs 70% (P < .05) and 85% vs 60% (P < .01), respectively. Patients carrying both ABCB1 and VEGF WT had the poorest 3-year PFS (46%) and overall survival (76%); in fact, in these patients, LEN did not improve PFS vs OBS (3-year PFS, 44% vs 60%; P = .62). Moreover, the CRBN polymorphism (n = 28) was associated with lenalidomide dose reduction or discontinuation. Finally, ABCB1, NCF4, and GSTP1 polymorphisms predicted lower hematological toxicity during induction, whereas ABCB1 and CRBN polymorphisms predicted lower risk of grade ≥3 infections. This study demonstrates that specific SNPs represent candidate predictive biomarkers of immunochemotherapy toxicity and LEN efficacy after ASCT in MCL | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 700 | 1 | |a Grimaldi, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Arrigoni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Pironti, Mariapia |e verfasserin |4 aut | |
| 700 | 1 | |a Zaccaria, Gian Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Alessandria, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Genuardi, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Ghislieri, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Tavarozzi, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Di Rocco, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Re, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Stefoni, Vittorio |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Boccomini, Carola |e verfasserin |4 aut | |
| 700 | 1 | |a Balzarotti, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Zilioli, Vittorio |e verfasserin |4 aut | |
| 700 | 1 | |a Moita, Filipa |e verfasserin |4 aut | |
| 700 | 1 | |a Arcaini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Lucchini, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ballerini, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreri, Andrés J M |e verfasserin |4 aut | |
| 700 | 1 | |a Puccini, Benedetta |e verfasserin |4 aut | |
| 700 | 1 | |a Palumbo, Giuseppe A |e verfasserin |4 aut | |
| 700 | 1 | |a Galimberti, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Cortelazzo, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Di Paolo, Antonello |e verfasserin |4 aut | |
| 700 | 1 | |a Ladetto, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 7(2023), 14 vom: 25. Juli, Seite 3764-3774 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:14 |g day:25 |g month:07 |g pages:3764-3774 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2022009504 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 14 |b 25 |c 07 |h 3764-3774 | ||